2018 Update of French Recommendations on ...
Type de document :
Compte-rendu et recension critique d'ouvrage
PMID :
Titre :
2018 Update of French Recommendations on the Management of Postmenopausal Osteoporosis
Auteur(s) :
Briot, Karine [Auteur correspondant]
Service de rhumatologie [CHU Cochin]
Roux, Christian [Auteur]
Service de rhumatologie [CHU Cochin]
Thomas, Thierry [Auteur]
Biologie Intégrative du Tissu Osseux [LBTO]
Blain, Hubert [Auteur]
Hôpital Lapeyronie [Montpellier] [CHU]
Buchon, Daniel [Auteur]
Chapurlat, Roland [Auteur]
Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases [LYOS]
Debiais, Françoise [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Feron, Jean Marc [Auteur]
CHU Saint-Antoine [AP-HP]
Gauvain, Jean Bernard [Auteur]
Centre Hospitalier Régional d'Orléans [CHRO]
Guggenbuhl, Pascal [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Legrand, Eric [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Lehr-Drylewicz, Anne Marie [Auteur]
Lespessailles, Eric [Auteur]
Centre Hospitalier Régional d'Orléans [CHRO]
Tremollieres, Françoise [Auteur]
Centre de Ménopause [CHU Toulouse]
Weryha, Georges [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Cortet, Bernard [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab (ex-pmoi)]
Service de rhumatologie [CHU Cochin]
Roux, Christian [Auteur]
Service de rhumatologie [CHU Cochin]
Thomas, Thierry [Auteur]
Biologie Intégrative du Tissu Osseux [LBTO]
Blain, Hubert [Auteur]
Hôpital Lapeyronie [Montpellier] [CHU]
Buchon, Daniel [Auteur]
Chapurlat, Roland [Auteur]
Physiopathologie, diagnostic et traitements des maladies osseuses / Pathophysiology, Diagnosis & Treatments of Bone Diseases [LYOS]
Debiais, Françoise [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Feron, Jean Marc [Auteur]
CHU Saint-Antoine [AP-HP]
Gauvain, Jean Bernard [Auteur]
Centre Hospitalier Régional d'Orléans [CHRO]
Guggenbuhl, Pascal [Auteur]
Nutrition, Métabolismes et Cancer [NuMeCan]
Legrand, Eric [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Lehr-Drylewicz, Anne Marie [Auteur]
Lespessailles, Eric [Auteur]
Centre Hospitalier Régional d'Orléans [CHRO]
Tremollieres, Françoise [Auteur]
Centre de Ménopause [CHU Toulouse]
Weryha, Georges [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Cortet, Bernard [Auteur]
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490 [MABLab (ex-pmoi)]
Titre de la revue :
Joint Bone Spine
Pagination :
519-530
Éditeur :
Elsevier Masson
Date de publication :
2018-10
ISSN :
1297-319X
Mot(s)-clé(s) en anglais :
Osteoporosis
Menopause
FRAX
Bone absorptiometry
Recommendations
Fracture
Menopause
FRAX
Bone absorptiometry
Recommendations
Fracture
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Rhumatologie et système ostéo-articulaire
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Gynécologie et obstétrique
Sciences du Vivant [q-bio]/Santé publique et épidémiologie
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Gynécologie et obstétrique
Sciences du Vivant [q-bio]/Santé publique et épidémiologie
Résumé en anglais : [en]
Objectives - To update the 2012 recommendations on pharmacotherapy for postmenopausal osteoporosis, under the aegis of the Bone Task Force of the French Society for Rheumatology (SFR) and of the Osteoporosis Research and ...
Lire la suite >Objectives - To update the 2012 recommendations on pharmacotherapy for postmenopausal osteoporosis, under the aegis of the Bone Task Force of the French Society for Rheumatology (SFR) and of the Osteoporosis Research and Information Group (GRIO), in collaboration with scientific societies (Collège national des généralistes enseignants, Collège national des gynécologues et obstétriciens français, Fédération nationale des collèges de gynécologie médicale, Groupe d'étude de la ménopause et du vieillissement hormonal, Société française de chirurgie orthopédique, Société française d'endocrinologie, and Société française de gériatrie et de gérontologie). Methods - Updated recommendations were developed by a task force whose members represented the medical specialties involved in the management of postmenopausal osteoporosis. The update was based on a literature review and developed using the method advocated by the French National Authority for Health (HAS). Discussion and conclusion - The updated recommendations place strong emphasis on the treatment of women with severe fractures, in whom the use of osteoporosis medications is recommended. All the available osteoporosis medications are suitable in patients with severe fractures; zoledronic acid deserves preference as the fist-line drug after a hip fracture. In patients with or without non-severe fractures, the decision to use osteoporosis medications is based on bone mineral density values and in challenging cases, on probabilities supplied by prediction tools such as FRAX. All osteoporosis medications are suitable; raloxifene should be reserved for patients at low risk for peripheral fractures. The fracture risk should be reevaluated every 2 to 3 years to decide on the best follow-up treatment. These updated recommendations discuss the selection of first-line osteoporosis medications and treatment sequences.Lire moins >
Lire la suite >Objectives - To update the 2012 recommendations on pharmacotherapy for postmenopausal osteoporosis, under the aegis of the Bone Task Force of the French Society for Rheumatology (SFR) and of the Osteoporosis Research and Information Group (GRIO), in collaboration with scientific societies (Collège national des généralistes enseignants, Collège national des gynécologues et obstétriciens français, Fédération nationale des collèges de gynécologie médicale, Groupe d'étude de la ménopause et du vieillissement hormonal, Société française de chirurgie orthopédique, Société française d'endocrinologie, and Société française de gériatrie et de gérontologie). Methods - Updated recommendations were developed by a task force whose members represented the medical specialties involved in the management of postmenopausal osteoporosis. The update was based on a literature review and developed using the method advocated by the French National Authority for Health (HAS). Discussion and conclusion - The updated recommendations place strong emphasis on the treatment of women with severe fractures, in whom the use of osteoporosis medications is recommended. All the available osteoporosis medications are suitable in patients with severe fractures; zoledronic acid deserves preference as the fist-line drug after a hip fracture. In patients with or without non-severe fractures, the decision to use osteoporosis medications is based on bone mineral density values and in challenging cases, on probabilities supplied by prediction tools such as FRAX. All osteoporosis medications are suitable; raloxifene should be reserved for patients at low risk for peripheral fractures. The fracture risk should be reevaluated every 2 to 3 years to decide on the best follow-up treatment. These updated recommendations discuss the selection of first-line osteoporosis medications and treatment sequences.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Collections :
Source :
Fichiers
- document
- Accès libre
- Accéder au document
- Briot%20et%20al_2018%20Update%20of%20French%20Recommendations%20on%20the%20Management%20of%20Postmenopausal.pdf
- Accès libre
- Accéder au document
- Briot%20et%20al_2018%20Update%20of%20French%20Recommendations%20on%20the%20Management%20of%20Postmenopausal.pdf
- Accès libre
- Accéder au document